SureNano Science Ltd. (SURNF)
| Market Cap | 3.53M +88.0% |
| Revenue | n/a |
| Net Income | n/a |
| EPS | n/a |
| Shares Out | n/a |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 5,000 |
| Open | 0.1040 |
| Previous Close | 0.0799 |
| Day's Range | 0.1040 - 0.1040 |
| 52-Week Range | 0.0724 - 0.3000 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | n/a |
About SureNano Science
SureNano Science Ltd. engages in the distribution and sale of surfactant in Canada and the United States. It provides SureNano surfactant, a ready-to-mix food-grade compound that provides the base for high performance nano-emulsions to create homogeneous and stable products. The company was incorporated in 2021 and is headquartered in Vancouver, Canada. [Read more]
News
NetworkNews Audio Announces Audio Press Release (APR) Discussing Overcoming Limitations on First-Generation GLP-1 Drug Therapies
AUSTIN, Texas, May 15, 2026 (GLOBE NEWSWIRE) -- via IBN – NetworkNewsAudio announces the Audio Press Release (APR) titled “The Next Generation of the GLP-1 Revolution Is Already Underway,” featuring S...
SureNano Science Ltd. (CSE: SURE) (OTCQB: SURNF) Developing Distinct Next-Gen GLP-1 Built Around Novel Peptide
Disseminated on behalf of SureNano Science Ltd. (CSE: SURE) (OTCQB: SURNF) and may include paid advertising.
SureNano Science Ltd. (CSE: SURE) (OTCQB: SURNF) Advancing a Differentiated Next-Gen GLP-1 Platform
Disseminated on behalf of SureNano Science Ltd. (CSE: SURE) (OTCQB: SURNF) and may include paid advertising.
SureNano Science Initiates FDA Stage GLP Toxicology and Pharmacology Studies for GLP GEP-44 and Enters Discussions to Acquire Ibogaine Formulation IP Portfolio
GLP-compliant program covering rodents, non-rodents, and primates will define safety, MTD and safe dose ranges, targeting weight loss and TIIDM Novel Ibogaine formulation development for mental health...
SureNano Science Ltd. Acquires GlucaPharm Inc., Advancing Second-Generation FDA Pathway GLP-1 Drug Development
GlucaPharm is developing GEP44, a novel, patented peptide (similar in function to Ozempic®, Wegovy®, Mounjaro®, but with reduced risk of adverse events) discovered by researchers at Syracuse Universit...
SureNano Announces Stock Option Grant
Vancouver, British Columbia--(Newsfile Corp. - December 12, 2025) - SureNano Science Ltd. (CSE: SURE) (OTCQB: SURNF) (the "Company" or "SureNano") announces that it has granted 1,500,000 stock options...
SureNano Announces Closing of $1,250,000 Private Placement
Vancouver, British Columbia--(Newsfile Corp. - December 10, 2025) - SureNano Science Ltd. (CSE: SURE) (OTCQB: SURNF) (the "Company" or "SureNano") is pleased to announce, as a follow-up to its news re...
SureNano Announces Non-Binding Letter of Intent to Negotiate Proposed Transaction of GlucaPharm Inc. for GLP-1 Drug Development
Vancouver, British Columbia--(Newsfile Corp. - November 19, 2025) - SureNano Science Ltd. (CSE: SURE) (OTCQB: SURNF) (the "Company" or "SureNano") is pleased to announce it has entered into a non-bind...
SureNano Announces Private Placement
Vancouver, British Columbia--(Newsfile Corp. - November 5, 2025) - SURENANO SCIENCE LTD. (CSE: SURE) (OTCQB: SURNF) (the "Company" or "SureNano") announces its intention to complete a private placemen...
SureNano Closes Financing
Vancouver, British Columbia--(Newsfile Corp. - September 19, 2025) - SURENANO SCIENCE LTD. (CSE: SURE) (OTCQB: SURNF) (the "Company" or "SureNano") announces that it has closed a private placement fin...
SureNano Announces Funding, Debt Settlement and AGSM Results
Vancouver, British Columbia--(Newsfile Corp. - August 22, 2025) - SURENANO SCIENCE LTD. (CSE: SURE) (OTCQB: SURNF) (the "Company" or "SureNano") announces its intention to complete a recapitalization ...